Health
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease – PRNewswire
/PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical…
LEXINGTON, Mass., March 24, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with mild-to-moderate AD. Participants were evaluated for safety and tolerability, as well as cognitive function and markers of AD pathology. Professor Huntington Potter, together with Jonathan Woodcock, Timothy…
-
General14 hours agoMatildas vs Panama international friendly — live blog and scores from Bunbury
-
Noosa News17 hours agoSearch for man who ‘faked death’ slowed by unusual French law
-
Noosa News19 hours agoAustralia’s biggest sheep drive, and the young drover history forgot
-
Noosa News15 hours agoPolice appeal for information after two men found dead